Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2023

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities consist of the following (in thousands): 

	As of
	June 30, 2023		December 31, 2022
Salaries and benefits	$	55,701	$	44,304
Incentive compensation	27,578		30,254
Operating lease liability-ST	19,187		18,169
Accrued sales taxes	6,043		5,844
Restructuring accrual	4,771		5,923
Deferred revenue	27,686		30,838
Accrued other taxes	3,960		5,794
Accrued professional fees	6,730		5,317
Italy medical device payback provision(2)	22,360		7,900
Legal accrual	2,667		3,137
Distribution fees	14,041		17,063
Warranties and returns	3,530		3,097
Field service corrective action(1)	28,684		24,517
Accrued freight	14,820		17,988
Foreign exchange contracts	3,806		1,847
Accrued research and development	2,211		3,538
Accrued audit fees	7,031		6,279
Defined benefit plan	2,331		2,928
Accrued interest	716		1,033
Other	655		6,999
	$	254,508	$	242,769

___________________________

(1)     Relates to field service corrective actions associated with certain products in connection with a 2021 Warning Letter received by Smiths Medical from the FDA following an inspection of Smiths Medical’s Oakdale, Minnesota Facility, see Note 19: Commitments and Contingencies for further detail.

(2)    As of December 31, 2022, there was $12.1 million in payback provision recorded as a reduction to accounts receivable, net. The Company reclassified such amount to accrued liabilities as of June 30, 2023. This amount was not reclassified as of December 31, 2022 to conform to the current year presentation.

Other long-term liabilities consist of the following (in thousands): 

	As of
	June 30, 2023		December 31, 2022
Operating lease liability-LT	$	59,875	$	60,916
Benefits	5,084		5,314
Accrued rent	930		997
Finance lease liability-LT	2,134		1,855
Deferred revenue	15,356		16,239
Field service corrective action(1)	22,849		25,294
Other	3,630		3,489
	$	109,858	$	114,104